| Lupin as entered into an Exclusive Licensing Agreement with Valorum Biologics (Valorum), a biosimilar specialist in the U.S., for its biosimilar Armlupeg™ (pegfilgrastim-unne).
Under the terms of the agreement, Valorum will advance the commercialization and distribution of Armlupeg™ (pegfilgrastim-unne) in the United States. Lupin will be responsible for manufacturing
and supply of the product and will receive an upfront license fee and a royalty payment on net sales.
Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. |